N-terminal pro Brain Natriuretic Peptide as predictor of outcome in scleroderma renal crisis

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages 122-128

  Chighizola, Cecilia B ^a,b   Pregnolato, Francesca ^b   Meroni, Pier Luigi ^a,b   Denton, Christopher P ^c   Ong, Voon H ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Dialysis; N TproBNP; Outcome; Scleroderma renal crisis; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; HEMOGLOBIN; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE DURATION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DISEASE; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN FUNCTION; RETROSPECTIVE STUDY; SCLERODERMA; SCLERODERMA RENAL CRISIS; AREA UNDER THE CURVE; BLOOD; COMPLICATION; CONVALESCENCE; GLOMERULUS FILTRATION RATE; HYPERTENSION; KIDNEY; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOPHYSIOLOGY; PRINCIPAL COMPONENT ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RENAL INSUFFICIENCY; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTOR; SCLERODERMA, SYSTEMIC; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BIOMARKERS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; LIKELIHOOD FUNCTIONS; LINEAR MODELS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PRINCIPAL COMPONENT ANALYSIS; RECOVERY OF FUNCTION; RENAL INSUFFICIENCY; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SCLERODERMA, SYSTEMIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84994389379     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. TRAUB YM, SHAPIRO AP, RODNAN GP et al.: Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 1983; 62: 335-52.
2. PENN H, DENTON CP: Diagnosis, management and prevention of scleroderma renal crisis. Curr Opin Rheumatol 2008; 20: 692-6.
3. PENN H, HOWIE AJ, KINGDON EJ et al.: Scleroderma renal crisis: patient characteristics and long-term outcomes. Q J Med 2007; 100: 485-94.
4. BARSOTTI S, STAGNARO C, DELLA ROSSA A: Systemic sclerosis: a critical digest of the recent literature. Clin Exp Rheumatol 2015; 33: S3-14.
5. STEEN VD, MESDGER TA: Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613-9.
6. MEYER O, DE CHAISEMARTIN L, NICAISEROLAND P et al.: Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol 2010; 37: 125-30.
7. STEEN VD, MEDSGER TA: Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133: 600-3.
8. DeMARCO PJ, WEISMAN MH, SEIBOLD JR et al.: Predictors and outcomes of scleroderma renal crisis. The high-dose versus low-dose Dpenicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46: 2983-9.
9. STEEN VD, CONSTANTINO JP, SHAPIRO AP, MESDGER TA: Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113: 352-7.
10. TEIXEIRA L, MAHR A, BEREZNE A, NOËL LH, GUILLEVIN L, MOUTHON L: Scleroderma renal crisis, still a life-threatening complication. Ann N Y Acad Sci 2007; 1108: 249-58.
11. DENTON CP, BLACK CM: Scleroderma-clinical and pathological advances. Best Pract Res Clin Rheumatol 2004; 18: 271-90.
12. BATAL I, DOMSIC RT, SHAFER A et al.: Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol 2009; 40: 332-40.
13. HALL C: Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004; 257-60.
14. WILLIAMS MH, HANDLER CE, AKRAM R et al.: Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27: 1485-94.
15. IBRAHIM N, JANUZZI JL: The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. Expert Rev Cardiovasc Ther 2015; 21: 1-14.
16. GIORDANO N, MONTELLA A, CORALLO C et al.: Pulmonary hypertension: a correct diagnosis for a suitable therapy in scleroderma patients. Clin Exp Rheumatol 2015; 33: S182-9.
17. ZOCCALI C, MALLAMACI F, BENEDETTO FA et al.: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12: 1508-15.
18. WANG AY, LAM CW, YU CM et al.: N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007; 18: 321-30.
19. MADSEN LH, LADEFOGED S, CORELL P, SCHOU M, HILDEBRANDT PR, ATAR D: Nterminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007; 71: 548-54.
20. van den HOOGEN F, KHANNA D, FRANSEN J et al.: 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
21. LEROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1998; 15: 202-5.
22. STEEN V, MAYES M, MERKEL P: Assessment of kidney involvement. Clin Exp Rheumatol 2003; 21: 29-31.
23. WALKER JG, AHERN MJ, SMITH MD et al.: Scleroderma renal crisis: poor outcome despite aggressive anti-hypertensive treatment. Intern Med J 2003; 216-20.
24. van KIMMENADE RR, JANUZZI JL, BAGGISH AL et al.: Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol 2006; 48: 1621-7.
25. DAS SR, ABDULLAH SM, LEONARD D et al.: Association between renal function and circulating levels of natriuretic peptides (from the Dallas Heart study). Am J Cardiol 2008; 102: 1394-8.
26. TAKAMI Y, HORIO T, IWASHIMA Y et al.: Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis dependent CRF. Am J Kidney Dis 2004; 44: 420-8.
27. CHOI HJ, SHIN YK, LEE HJ et al.: The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis. Clin Rheumatol 2008; 27: 437-42.
28. ORAVEC RM, BREDEMEIER M, LAURINO CC et al.: NTproBNP levels in systemic sclerosis: association with clinical and laboratory abnormalities. Clinical Biochem 2010; 43: 745-9.
29. SCHIOPPO T, ARTUSI C, CIAVARELLA T et al.: N-TproBNP as biomarker in systemic sclerosis. Clin Rev Allergy Immunol 2012; 43: 292-301.
30. TEXEIRA L, MOUTHON L, MAHR A et al.: Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67: 110-6.
31. REDFIELD MM, RODEHEFFER RJ, JACOBSEN SJ, MAHONEY DW, BAILEY KR, BURNETT JC Jr: Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Card 2002; 40: 976-82.
32. JANUZZI JL: The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arch Cardiovascular Dis 2012; 105: 40-50.
33. OLOFSSON M, BOMAN K: Usefulness of natriuretic peptides in primary health care: an exploratory study in elderly patients. Scand J Prim Health Care 2010; 28: 29-35.
34. McDONAGH TA, HOLMER S, RAYMOND I, LUCHNER A, HILDEBRANT P, DARGIE HJ: NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail 2004; 6: 269-73.
35. GUILLEVIN L, BEREZNE A, SEROR R et al.: Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford) 2012; 51: 460-7.
36. BALIK M, JABOR A, OTAHAL M, WALDAUF P, PAVLISOVA M: Impact of acute renal failure on the relationship between N-Terminal pro-B type natriuretic peptide and hemodynamic parameters. Blood Purif 2011; 31: 47-54.